Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin
| Autor: | Nicolas Isambert, Johan Vansteenkiste, R. Donald Harvey, Doris Weilert, Saeed Rafii, Karen Thomas, Karthick Vishwanathan, Paul A. Dickinson, Karen So, Khanh Bui |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research business.industry Pharmacology Multiple dose In vitro respiratory tract diseases stomatognathic diseases 03 medical and health sciences T790M 030104 developmental biology 0302 clinical medicine Oncology Pharmacokinetics Simvastatin 030220 oncology & carcinogenesis Mutation (genetic algorithm) Medicine Rosuvastatin Osimertinib business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 34:e14098-e14098 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2016.34.15_suppl.e14098 |
| Popis: | e14098Background: Osimertinib is a potent, oral, irreversible EGFR-TKI with efficacy in pts with EGFR-TKI sensitizing (EGFRm) and T790M mutation positive advanced NSCLC. In vitro data show osimerti... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|